TY - JOUR
T1 - American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
T2 - Version 4
AU - Curtis, Jeffrey R.
AU - Johnson, Sindhu R.
AU - Anthony, Donald D.
AU - Arasaratnam, Reuben J.
AU - Baden, Lindsey R.
AU - Bass, Anne R.
AU - Calabrese, Cassandra
AU - Gravallese, Ellen M.
AU - Harpaz, Rafael
AU - Kroger, Andrew
AU - Sadun, Rebecca E.
AU - Turner, Amy S.
AU - Williams, Eleanor Anderson
AU - Mikuls, Ted R.
N1 - Funding Information:
The task force would like to thank Regina Parker (ACR) for her role in coordinating the activities of the Task Force.
Publisher Copyright:
© 2022 American College of Rheumatology.
PY - 2022/5
Y1 - 2022/5
N2 - Objective: To provide guidance to rheumatology providers on the use of COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results: Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines, including supplemental/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion: These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
AB - Objective: To provide guidance to rheumatology providers on the use of COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results: Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines, including supplemental/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion: These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
UR - http://www.scopus.com/inward/record.url?scp=85128885301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128885301&partnerID=8YFLogxK
U2 - 10.1002/art.42109
DO - 10.1002/art.42109
M3 - Article
C2 - 35474640
AN - SCOPUS:85128885301
SN - 2326-5191
VL - 74
SP - 21-e36
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 5
ER -